CN109364035A - A kind of clonidine hydrochloride sustained release tablets and preparation method thereof - Google Patents
A kind of clonidine hydrochloride sustained release tablets and preparation method thereof Download PDFInfo
- Publication number
- CN109364035A CN109364035A CN201811454995.3A CN201811454995A CN109364035A CN 109364035 A CN109364035 A CN 109364035A CN 201811454995 A CN201811454995 A CN 201811454995A CN 109364035 A CN109364035 A CN 109364035A
- Authority
- CN
- China
- Prior art keywords
- parts
- clonidine hydrochloride
- sustained release
- release tablets
- hydrochloride sustained
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a kind of clonidine hydrochloride sustained release tablets and preparation method thereof, belong to field of pharmaceutical preparations.Clonidine hydrochloride sustained release tablets of the invention, consisting of: 0.1-0.5 parts of active constituent, 8-18 parts of composition polymer skeleton system, 10-18 parts of disintegrating agent, 12-18 parts of adhesive, 15-30 parts of diluent, 0.1-2 parts of lubricant, the active constituent is made of clonidine hydrochloride and scutellarin, and the composition polymer skeleton system is made of methylcellulose and polyvinyl alcohol.Clonidine hydrochloride and scutellarin use in conjunction are used to prepare the sustained release tablets of decompression by the present invention for the first time, by optimizing screening to formula, by effect test the study found that clonidine hydrochloride and scutellarin use in conjunction can significantly improve antihypertensive effect, synergistic function is achieved.
Description
Technical field
The present invention relates to field of pharmaceutical preparations, and in particular to a kind of clonidine hydrochloride sustained release tablets and preparation method thereof.
Background technique
Clonidine hydrochloride is the imidazolidine derivatives of early 1960s synthesis, is α 2- adrenoceptor agonists,
The directly central postsynaptic membrane α 2 receptor of excitement hypothalamus and medulla oblongata keeps inhibitory neuron excited, reduces central sympathetic
Impulsion outflow is clinically mainly used for treating hypertension, hypertension emergency, migraine to inhibit periphery sympathetic nerve activity,
Menopause hectic fever, dysmenorrhea and abstains paregorism toxication shape.
Currently, clonidine hydrochloride has listed preparation, there are tablet, dripping pill, injection and transdermal patchs etc..Clonidine hydrochloride is slow
It releases piece to be developed by AddrenexPharmaceuticals company of the U.S., the acquisition U.S. FDA approval on the 29th of September in 2009 is for controlling
Treat hypertension, specification: 0.1mg, 0.2mg.On September 30th, 2009, ShionogiPharma company has submitted additional hydrochloric acid to FDA
The new drug replacement demand of clonidine sustained release tablets indication, and in the acquisition U.S. FDA approval on the 28th of September in 2010 for treat 6~
The ADHD of 17 years old Children and teenagers, can be used as single therapy also can be used as the adjuvant drug of central stimulant, 0.1mg specification
Clonidine hydrochloride sustained release tablets are in January, 2011 in U.S.'s list marketing.
Scutellarin is the main chemical compositions of fleabane flower, modern pharmacology research show its with anti-inflammatory, anti-oxidant and
Anti-apoptotic and other effects, while having the function of expansion of cerebral vascular, cerebral vascular resistance can be reduced, cerebral blood flow (CBF) is increased, improves micro- follow
Ring, and have to antiplatelet aggregative activity, clinic is attended class for treating ischemic cerebrovascular disease.
In the prior art not by the research of clonidine hydrochloride and scutellarin use in conjunction.
Summary of the invention
The object of the present invention is to provide a kind of clonidine hydrochloride sustained release tablets and preparation method thereof that antihypertensive effect is excellent.
The technical solution that the present invention solves the technical problem is a kind of clonidine hydrochloride sustained release tablets, consisting of:
0.1-0.5 parts of active constituent
8-18 parts of composition polymer skeleton system
10-18 parts of disintegrating agent
12-18 parts of adhesive
15-30 parts of diluent
0.1-2 parts of lubricant
The active constituent is made of clonidine hydrochloride and scutellarin,
The composition polymer skeleton system is made of methylcellulose and polyvinyl alcohol.
Preferably, consisting of:
0.2-0.4 parts of active constituent
10-15 parts of composition polymer skeleton system
12-16 parts of disintegrating agent
14-16 parts of adhesive
18-26 parts of diluent
0.2-1 parts of lubricant
The active constituent is made of clonidine hydrochloride and scutellarin,
The composition polymer skeleton system is made of methylcellulose and polyvinyl alcohol.
It is furthermore preferred that consisting of:
0.3 part of active constituent
12 parts of composition polymer skeleton system
14 parts of disintegrating agent
15 parts of adhesive
22 parts of diluent
0.5 part of lubricant
The active constituent is made of clonidine hydrochloride and scutellarin,
The composition polymer skeleton system is made of methylcellulose and polyvinyl alcohol.
The weight part ratio of the clonidine hydrochloride and scutellarin is 1:1-3:1.
The weight ratio of the methylcellulose and polyvinyl alcohol is 1:4-4:1, it is preferred that the methylcellulose and poly- second
The weight ratio of enol is 4:1.
The diluent includes one of calcium phosphate, calcium sulfate, microcrystalline cellulose, dextrin and mannitol or a variety of.
Described adhesive includes one of lactose, amylum pregelatinisatum and povidone or a variety of.
The disintegrating agent includes one of dry starch, silica, alginic acid and crospovidone or a variety of.
Invention also provides the preparation methods of above-mentioned clonidine hydrochloride sustained release tablets, comprising the following steps: presses recipe ratio
Example weighs raw material, and active ingredient hydrochloric acid clonidine and scutellarin are uniformly mixed with composition polymer skeleton system, is added dilute
Release agent, adhesive, disintegrating agent and lubricant, pelletize, tabletting to get.
Beneficial effects of the present invention:
Clonidine hydrochloride and scutellarin use in conjunction are used to prepare the sustained release tablets of decompression by the present invention for the first time, by matching
Side optimizes screening, by effect test the study found that clonidine hydrochloride and scutellarin use in conjunction can significantly improve
Antihypertensive effect achieves synergistic function.
Specific embodiment
Present invention will be further explained below with reference to specific examples.It should be understood that these embodiments are merely to illustrate the present invention
Rather than it limits the scope of the invention.In the following examples, the experimental methods for specific conditions are not specified, usually according to conventional strip
Part or according to the normal condition proposed by manufacturer.Unless otherwise stated, otherwise all percentage, ratio, ratio or number is pressed
Poidometer.
Unless otherwise defined, all professional and scientific terms as used herein and meaning familiar to those skilled in the art
Justice is identical.In addition, any method similar to or equal to what is recorded and material can be applied to the method for the present invention.Wen Zhong
The preferred implement methods and materials are for illustrative purposes only.
The preparation of embodiment clonidine hydrochloride sustained release tablets
It is pelletized according to the weight formula of table 1, tabletting prepares clonidine hydrochloride sustained release tablets embodiment 1-3 and comparison
Example 1-2.
1 clonidine hydrochloride of table is sustained slice prescription
| Embodiment 1 | Embodiment 2 | Embodiment 3 | Comparative example 1 | Comparative example 2 | |
| Clonidine hydrochloride | 0.1 | 0.12 | 0.15 | 0.2 | 0 |
| Scutellarin | 0.1 | 0.08 | 0.05 | 0 | 0.2 |
| Methylcellulose | 12 | 12 | 12 | 12 | 12 |
| Polyvinyl alcohol | 3 | 3 | 3 | 3 | 3 |
| Dry starch | 6 | 6 | 6 | 6 | 6 |
| Crospovidone | 6 | 6 | 6 | 6 | 6 |
| Lactose | 15 | 15 | 15 | 15 | 15 |
| Calcium sulfate | 10 | 10 | 10 | 10 | 10 |
| Microcrystalline cellulose | 10 | 10 | 10 | 10 | 10 |
| Magnesium stearate | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 |
A clonidine hydrochloride sustained release tablets single-dose is tested to the blood pressure fall of spontaneous hypertensive rat (SHR)
It influences
The 10 week old male spontaneous hypertensive rats (SHR) of 90 weight 190-220g are randomly divided into 6 groups, every group 15
Only, respectively blank control group (distilled water), example 1 group (sustained release tablets of embodiment 1), 2 groups of embodiment (embodiment 2 it is slow
Release piece), 2 groups of 3 groups of embodiment (sustained release tablets of embodiment 3), 1 group of reference examples (sustained release tablets of comparative example 1) and reference examples (comparative examples
2 sustained release tablets).Whether blood pressure when measurement each group spontaneous hypertensive rat (SHR) is awake respectively before experiment observes it three times
Normally, abnormal rat then replaces.It is worth based on measurement blood pressure before administration, then gastric infusion respectively, after administration
1h, 2h, 4h, 6h, 8h, 12h, for 24 hours with 36h measure blood pressure, the results are shown in Table 2.
Shadow of the 2 clonidine hydrochloride sustained release tablets single-dose of table to the blood pressure fall of spontaneous hypertensive rat (SHR)
It rings
| Blank control group | Example 1 group | 2 groups of embodiment | 3 groups of embodiment | 1 group of reference examples | 2 groups of reference examples | |
| 0 | 181.23±4.23 | 182.34±4.34 | 184.34±5.21 | 184.32±3.43 | 188.43±1.32 | 182.98±5.34 |
| 1h | 181.45±3.45 | 148.45±2.24 | 151.76±2.54 | 148.34±2.45 | 162.67±1.24 | 170.23±2.32 |
| 2h | 182.34±1.43 | 150.23±1.45 | 153.87±1.24 | 149.34±2.34 | 169.54±2.34 | 169.45±3.45 |
| 4h | 184.23±2.32 | 149.23±2.76 | 152.46±1.83 | 150.26±2.41 | 161.24±2.45 | 171.34±3.54 |
| 6h | 182.32±1.32 | 151.24±1.66 | 151.98±1.35 | 148.26±3.04 | 169.45±2.54 | 172.23±2.34 |
| 8h | 181.98±2.43 | 152.58±2.98 | 153.34±1.45 | 149.54±2.78 | 169.34±2.45 | 168.45±3.42 |
| 12h | 183.43±1.89 | 152.26±3.01 | 150.45±1.23 | 151.23±2.31 | 168.34±3.68 | 168.89±4.35 |
| 24h | 183.54±1.54 | 153.34±1.56 | 154.98±2.45 | 153.25±2.54 | 168.34±4.24 | 171.65±1.56 |
| 36h | 183.34±2.43 | 170.54±3.45 | 171.23±2.56 | 170.34±2.43 | 180.65±1.56 | 180.45±3.35 |
According to result above it is found that each group single-dose is to the blood pressure fall of spontaneous hypertensive rat (SHR)
Influence it is different, wherein blank control group does not change due to taking distilled water blood pressure in 36h, under the blood pressure that 1 group of comparative example
Drop 20 or so, the blood pressure decline 12 or so that 2 groups of comparative example, and the blood pressure of embodiment 1-3 group decline 35 or so, significant effect.
Two clonidine hydrochloride sustained release tablets multiple dosings are tested to the blood pressure fall of spontaneous hypertensive rat (SHR)
It influences
The 10 week old male spontaneous hypertensive rats (SHR) of 90 weight 190-220g are randomly divided into 6 groups, every group 15
Only, respectively blank control group (distilled water), example 1 group (sustained release tablets of embodiment 1), 2 groups of embodiment (embodiment 2 it is slow
Release piece), 2 groups of 3 groups of embodiment (sustained release tablets of embodiment 3), 1 group of reference examples (sustained release tablets of comparative example 1) and reference examples (comparative examples
2 sustained release tablets).It is worth based on blood pressure when measurement spontaneous hypertensive rat is awake, then once a day, continuous two weeks,
Each group distinguishes gastric infusion.Before administration, administration after 2 hours and administration after (every other day) survey waking state respectively within 24 hours
The blood pressure of lower spontaneous hypertensive rat (SHR).Convalescence continues to measure the variation of SHR blood pressure after drug withdrawal, until index is restored
It is horizontal before to administration.The results are shown in Table 3.
Shadow of the 3 clonidine hydrochloride sustained release tablets multiple dosing of table to the blood pressure fall of spontaneous hypertensive rat (SHR)
It rings
| Blank control group | Example 1 group | 2 groups of embodiment | 3 groups of embodiment | 1 group of reference examples | 2 groups of reference examples | |
| 0 | 182.17±5.01 | 181.15±2.45 | 182.43±1.32 | 182.55±2.15 | 182.54±2.15 | 181.93±4.13 |
| 1d | 183.14±4.41 | 150.12±4.02 | 153.13±1.51 | 151.13±3.22 | 165.13±2.21 | 171.21±2.33 |
| 2d | 181.79±2.12 | 149.21±2.14 | 152.14±2.11 | 150.11±1.31 | 163.51±1.21 | 172.41±1.44 |
| 4d | 182.77±3.12 | 148.12±1.14 | 151.15±2.05 | 149.54±2.43 | 160.31±2.11 | 172.09±2.06 |
| 6d | 181.34±2.11 | 150.21±2.11 | 152.91±1.31 | 150.14±2.11 | 169.44±1.51 | 171.26±2.65 |
| 8d | 182.14±1.33 | 149.12±2.14 | 151.04±2.11 | 148.98±1.35 | 169.66±1.21 | 169.45±1.14 |
| 10d | 181.48±2.03 | 151.43±2.11 | 151.11±1.54 | 150.21±1.65 | 172.12±4.02 | 170.35±2.16 |
| 12d | 182.13±2.14 | 155.13±1.41 | 152.15±1.32 | 150.21±1.57 | 169.31±2.14 | 172.61±2.43 |
| 15d | 181.79±2.11 | 173.23±2.55 | 172.21±2.52 | 172.11±2.45 | 181.43±3.03 | 182.15±2.08 |
According to result above it is found that each group multiple dosing is to the blood pressure fall of spontaneous hypertensive rat (SHR)
Influence it is similar to the influence of blood pressure fall of the single-dose to spontaneous hypertensive rat (SHR), embodiment 1-3 group
Blood pressure declines by a big margin, and produces synergistic function.
The present invention is described in detail above, specific case used herein is to the principle of the present invention and implementation
Mode is expounded, and the above description of the embodiment is only used to help understand the method for the present invention and its core ideas, including
Best mode, and but also any person skilled in the art can practice the present invention, including any dress of manufacture and use
It sets or system, and implements the method for any combination.It should be pointed out that for those skilled in the art, not
, can be with several improvements and modifications are made to the present invention under the premise of being detached from the principle of the invention, these improvement and modification are also fallen into
In the protection scope of the claims in the present invention.The range of the invention patent protection is defined by the claims, and may include this
Field technical staff it is conceivable that other embodiments.If these other embodiments, which have, is not different from claim text
The structural element of statement, or if they include the equivalent structural elements with the character express of claim without essence difference,
So these other embodiments should also be included in the scope of the claims.
Claims (10)
1. a kind of clonidine hydrochloride sustained release tablets, which is characterized in that consisting of:
0.1-0.5 parts of active constituent
8-18 parts of composition polymer skeleton system
10-18 parts of disintegrating agent
12-18 parts of adhesive
15-30 parts of diluent
0.1-2 parts of lubricant
The active constituent is made of clonidine hydrochloride and scutellarin,
The composition polymer skeleton system is made of methylcellulose and polyvinyl alcohol.
2. clonidine hydrochloride sustained release tablets according to claim 1, which is characterized in that consisting of:
0.2-0.4 parts of active constituent
10-15 parts of composition polymer skeleton system
12-16 parts of disintegrating agent
14-16 parts of adhesive
18-26 parts of diluent
0.2-1 parts of lubricant
The active constituent is made of clonidine hydrochloride and scutellarin,
The composition polymer skeleton system is made of methylcellulose and polyvinyl alcohol.
3. clonidine hydrochloride sustained release tablets according to claim 2, which is characterized in that consisting of:
0.3 part of active constituent
12 parts of composition polymer skeleton system
14 parts of disintegrating agent
15 parts of adhesive
22 parts of diluent
0.5 part of lubricant
The active constituent is made of clonidine hydrochloride and scutellarin,
The composition polymer skeleton system is made of methylcellulose and polyvinyl alcohol.
4. clonidine hydrochloride sustained release tablets according to claim 1-3, which is characterized in that the clonidine hydrochloride and
The weight part ratio of scutellarin is 1:1-3:1.
5. clonidine hydrochloride sustained release tablets according to claim 1-3, which is characterized in that the methylcellulose and
The weight ratio of polyvinyl alcohol is 1:4-4:1.
6. clonidine hydrochloride sustained release tablets according to claim 5, which is characterized in that the methylcellulose and polyvinyl alcohol
Weight ratio be 4:1.
7. clonidine hydrochloride sustained release tablets according to claim 1-3, which is characterized in that the diluent includes phosphorus
One of sour calcium, calcium sulfate, microcrystalline cellulose, dextrin and mannitol are a variety of.
8. clonidine hydrochloride sustained release tablets according to claim 1-3, which is characterized in that described adhesive includes cream
One of sugar, amylum pregelatinisatum and povidone are a variety of.
9. clonidine hydrochloride sustained release tablets according to claim 1-3, which is characterized in that the disintegrating agent includes dry
One of dry starch, silica, alginic acid and crospovidone are a variety of.
10. the preparation method of -9 described in any item clonidine hydrochloride sustained release tablets according to claim 1, it is characterised in that including with
Lower step: weighing raw material by formula rate, by active ingredient hydrochloric acid clonidine and scutellarin and composition polymer skeleton system
Be uniformly mixed, be added diluent, adhesive, disintegrating agent and lubricant, granulation, tabletting to get.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811454995.3A CN109364035B (en) | 2018-11-30 | 2018-11-30 | Clonidine hydrochloride sustained release tablet and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811454995.3A CN109364035B (en) | 2018-11-30 | 2018-11-30 | Clonidine hydrochloride sustained release tablet and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109364035A true CN109364035A (en) | 2019-02-22 |
| CN109364035B CN109364035B (en) | 2021-02-09 |
Family
ID=65375505
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811454995.3A Active CN109364035B (en) | 2018-11-30 | 2018-11-30 | Clonidine hydrochloride sustained release tablet and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109364035B (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101125126A (en) * | 2006-08-16 | 2008-02-20 | 丛繁滋 | Method for preparing medical freeze-dried powder (injection) preparation |
| WO2013131270A1 (en) * | 2012-03-08 | 2013-09-12 | Liu Li | Scutellarin hydrate and preparation method and use thereof |
| CN103705531A (en) * | 2013-12-20 | 2014-04-09 | 昆明医科大学 | Application of scutellarin in preventing and treating specific vascular endothelial injury |
| CN105288648A (en) * | 2015-10-14 | 2016-02-03 | 东南大学 | Phospholipid compound of hydrophilic drugs as well as pharmaceutical composition and application of phospholipid compound |
| CN105395506A (en) * | 2015-12-07 | 2016-03-16 | 青岛正大海尔制药有限公司 | Clonidine hydrochloride sustained-release tablet |
| CN105395518A (en) * | 2015-12-07 | 2016-03-16 | 青岛正大海尔制药有限公司 | Clonidine hydrochloride sustained-release capsule |
| WO2016192680A1 (en) * | 2015-06-03 | 2016-12-08 | Triastek, Inc. | Dosage forms and use thereof |
-
2018
- 2018-11-30 CN CN201811454995.3A patent/CN109364035B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101125126A (en) * | 2006-08-16 | 2008-02-20 | 丛繁滋 | Method for preparing medical freeze-dried powder (injection) preparation |
| WO2013131270A1 (en) * | 2012-03-08 | 2013-09-12 | Liu Li | Scutellarin hydrate and preparation method and use thereof |
| CN103705531A (en) * | 2013-12-20 | 2014-04-09 | 昆明医科大学 | Application of scutellarin in preventing and treating specific vascular endothelial injury |
| WO2016192680A1 (en) * | 2015-06-03 | 2016-12-08 | Triastek, Inc. | Dosage forms and use thereof |
| CN105288648A (en) * | 2015-10-14 | 2016-02-03 | 东南大学 | Phospholipid compound of hydrophilic drugs as well as pharmaceutical composition and application of phospholipid compound |
| CN105395506A (en) * | 2015-12-07 | 2016-03-16 | 青岛正大海尔制药有限公司 | Clonidine hydrochloride sustained-release tablet |
| CN105395518A (en) * | 2015-12-07 | 2016-03-16 | 青岛正大海尔制药有限公司 | Clonidine hydrochloride sustained-release capsule |
Non-Patent Citations (4)
| Title |
|---|
| JIALIANG GAO ET AL.: "Therapeutic Effects of Breviscapine in Cardiovascular Diseases: A Review", 《FRONTIERS IN PHARMACOLOGY》 * |
| 张莲莲等: "注射用灯盏花素联合厄贝沙坦片治疗早期糖尿病肾病疗效观察", 《中国民康医学》 * |
| 潘卫三主编: "《工业药剂学》", 31 August 2015, 中国医药科技出版社 * |
| 邱英等: "ARB类药物联合灯盏花素治疗糖尿病肾病的有效性及安全性", 《山东医药》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109364035B (en) | 2021-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105646584B (en) | Tenofovir Chinese mugwort draws phenol amine fumarate crystal form and its preparation method and application | |
| CN101695480B (en) | Olopatadine hydrochloride dispersible tablets, preparation method thereof and quality control method thereof | |
| CN101375849A (en) | Novel dosage form of sinomenine medicament or hydrochlorate thereof and preparation technique thereof | |
| CN101647797A (en) | Pharmaceutical composition containing Amlodipine besilate and valsartan and preparation method thereof | |
| CN109364035A (en) | A kind of clonidine hydrochloride sustained release tablets and preparation method thereof | |
| WO2014101115A1 (en) | Montelukast sodium tablet composition and preparation method thereof | |
| US11944661B2 (en) | Pharmaceutical composition containing extract of leaves of Vaccinium bracteatum Thunb. for prevention or treatment of stress disease and depression | |
| CN109453162A (en) | Application, pharmaceutical composition and application of the amentoflavone in preparation protection and/or reparation nerve cell drug | |
| CN103751141A (en) | Rupatadine fumarate tablets and preparation method thereof | |
| CN106420637B (en) | A kind of Determination of Ketotifen Fumarate Tablets and preparation method thereof | |
| US9161930B2 (en) | Pharmaceutical composition for diabetic nephropathy and its preparation and application | |
| CN110522756B (en) | Application of gypenoside LVI in preparation of antidepressant | |
| CN102552197A (en) | Tablet containing febuxostat and preparation method of the tablet | |
| CN102008525A (en) | Pellet of celery seed extract and preparation method thereof | |
| CN105395518B (en) | A kind of clonidine hydrochloride spansule | |
| CN105748424A (en) | Stable clopidogrel bisulfate aspirin double-layer tablet and preparation method thereof | |
| CN109646417A (en) | A kind of Trimetazidine sustained release tablets and preparation method thereof | |
| CN114010615A (en) | Donepezil hydrochloride sustained-release tablet and preparation method thereof | |
| CN109260168B (en) | Clonidine hydrochloride sustained release tablet | |
| CN104069486B (en) | A kind of pharmaceutical composition and preparation thereof containing kallidinogenase | |
| CN110833540A (en) | Salicorol, caffeine and chlorphenamine maleate tablet and preparation method thereof | |
| CN109662948B (en) | Platelet aggregation inhibitor and preparation method thereof | |
| CN113768889B (en) | Cilostazol-containing pharmaceutical composition and preparation method thereof | |
| CN108498472B (en) | Olanzapine tablet and preparation method thereof | |
| CN103467364B (en) | Manidipine hydrochloride compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |